Ferment B. Arnulf B [CAR-T cells immunotherapy in multiple myeloma: present and future]. Bull Cancer. 2021;108:S65–72.

Article  PubMed  Google Scholar 

Guha P, Heatherton KR, O’Connell KP, Alexander IS, Katz SC. Assessing the future of solid tumor immunotherapy. Biomedicines. 2022;10:655.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park JH, Riviere I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Varadhachary AS, Perdow SN, Hu C, Ramanarayanan M, Salgame P. Differential ability of T cell subsets to undergo activation-induced cell death. Proc Natl Acad Sci U S A. 1997;94:5778–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huan T, Chen D, Liu G, et al. Activation-induced cell death in CAR-T cell therapy. Hum Cell. 2022;35:441–7.

Article  CAS  PubMed  Google Scholar 

Gargett T, Yu W, Dotti G, et al. GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Mol Ther. 2016;24:1135–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Long AH, Haso WM, Shern JF, et al. 4–1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21:581–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu J, Petit PF, Van den Eynde BJ. Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism. Cancer Immunol Immunother. 2019;68:835–47.

Article  CAS  PubMed  Google Scholar 

Wolf BB, Green DR. Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem. 1999;274:20049–52.

Article  CAS  PubMed  Google Scholar 

Kennedy R, Celis E. T helper lymphocytes rescue CTL from activation-induced cell death. J Immunol. 2006;177:2862–72.

Article  CAS  PubMed  Google Scholar 

Huang D, Chen J, Yang L, et al. NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nat Immunol. 2018;19:1112–25.

Article  CAS  PubMed  Google Scholar 

Kasibhatla S, Genestier L, Green DR. Regulation of fas-ligand expression during activation-induced cell death in T lymphocytes via nuclear factor kappaB. J Biol Chem. 1999;274:987–92.

Article  CAS  PubMed  Google Scholar 

Serfling E, Berberich-Siebelt F, Avots A, et al. NFAT and NF-kappaB factors-the distant relatives. Int J Biochem Cell Biol. 2004;36:1166–70.

Article  CAS  PubMed  Google Scholar 

Nguyen T, Russell J. The regulation of FasL expression during activation-induced cell death (AICD). Immunology. 2001;103:426–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Porichis F, Morou A, Baritaki S, Spandidos DA, Krambovitis E. Activation-induced cell death signalling in CD4+ T cells by staphylococcal enterotoxin A. Toxicol Lett. 2008;176:77–84.

Article  CAS  PubMed  Google Scholar 

Bajgain P, Torres Chavez AG, Balasubramanian K, et al. Secreted fas decoys enhance the antitumor activity of engineered and bystander T cells in fas ligand-expressing solid tumors. Cancer Immunol Res. 2022;10:1370–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tschumi BO, Dumauthioz N, Marti B, et al. CART cells are prone to fas- and DR5-mediated cell death. J Immunother Cancer. 2018;6:71.

Article  PubMed  PubMed Central  Google Scholar 

Ren J, Zhang X, Liu X, et al. A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget. 2017;8:17002–11.

Article  PubMed  PubMed Central  Google Scholar 

Kari S, Subramanian K, Altomonte IA, Murugesan A, Yli-Harja O, Kandhavelu M. Programmed cell death detection methods: a systematic review and a categorical comparison. Apoptosis. 2022;27:482–508.

Article  PubMed  PubMed Central  Google Scholar 

Lalier L, Vallette F, Manon S. Bcl-2 family members and the mitochondrial import machineries: the roads to death. Biomolecules. 2022;12:162.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chhabra A. Mitochondria-centric activation induced cell death of cytolytic T lymphocytes and its implications for cancer immunotherapy. Vaccine. 2010;28:4566–72.

Article  CAS  PubMed  Google Scholar 

Strasser A, Harris AW, Huang DC, Krammer PH, Cory S. Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J. 1995;14:6136–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chhabra A, Mehrotra S, Chakraborty NG, Dorsky DI, Mukherji B. Activation-induced cell death of human melanoma specific cytotoxic T lymphocytes is mediated by apoptosis-inducing factor. Eur J Immunol. 2006;36:3167–74.

Article  CAS  PubMed  Google Scholar 

Yu F, Gao Y, Wu Y, et al. Combination of a novel fusion protein CD3epsilonzeta28 and bispecific T cell engager enhances the persistance and anti-cancer effects of T cells. Cancers (Basel). 2022;14:4947.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chagoya G, Kwatra SG, Nanni CW, et al. Efficacy of osimertinib against EGFRvIII+ glioblastoma. Oncotarget. 2020;11:2074–82.

Article  PubMed  PubMed Central  Google Scholar 

Paff M, Alexandru-Abrams D, Hsu FP, Bota DA. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients. Hum Vaccin Immunother. 2014;10:3322–31.

Article  PubMed  Google Scholar 

Zhang X, Lv X, Song Y. Short-term culture with IL-2 is beneficial for potent memory chimeric antigen receptor T cell production. Biochem Biophys Res Commun. 2018;495:1833–8.

Article  CAS  PubMed  Google Scholar 

Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu Rev Immunol. 1998;16:395–419.

Article  CAS  PubMed  Google Scholar 

Chmielewski M, Abken H. CAR T cells releasing IL-18 convert to T-bet(high) FoxO1(low) effectors that exhibit augmented activity against advanced solid tumors. Cell Rep. 2017;21:3205–19.

Article  CAS  PubMed  Google Scholar 

Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15:1145–54.

Article  CAS  PubMed